NASDAQ : TLSI
TriSalus Life Sciences, Inc. — Key statistics
Healthcare · Medical Devices · United States
Last price 3.7 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 227.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 223.52M |
| Enterprise Value | 211.65M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 61.57M |
| Shares Outstanding | 61.57M |
| Shares Change (YoY) | +73.15% |
| Shares Change (QoQ) | +11.44% |
| Owned by Insiders (%) | 16.75% |
| Owned by Institutions (%) | 54.95% |
| Float | 49.81M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.96 |
| Forward PS | 3.30 |
| PB Ratio | 34.07 |
| P/TBV Ratio | 34.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.70 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.35 |
| Quick Ratio | 4.72 |
| Debt / Equity | 5.26 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.23 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -36.75% |
| Return on Invested Capital (ROIC) | -69.07% |
| Return on Capital Employed (ROCE) | -59.50% |
| Weighted Average Cost of Capital (WACC) | 7.71% |
| Revenue Per Employee | $441,931 |
| Profits Per Employee | -$561,265 |
| Employee Count | 102 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 1.60 |
Taxes
| Measure | Value |
|---|
| Income Tax | 13,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -23.42% |
| 50-Day Moving Average | 4.40 |
| 200-Day Moving Average | 4.39 |
| Relative Strength Index (RSI) | 36.55 |
| Average Volume (20 Days) | 143,301 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.44M |
| Short Previous Month | 3.35M |
| Short % of Shares Out | 5.59% |
| Short % of Float | 6.92% |
| Short Ratio (days to cover) | 7.52 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 45.08M |
| Gross Profit | 38.67M |
| Operating Income | -30.51M |
| Pretax Income | -28.20M |
| Net Income | -57.25M |
| EBITDA | -29.95M |
| EBIT | -30.51M |
| Loss Per Share | -$1.15 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 46.29M |
| Total Debt | 34.43M |
| Net Cash | 11.86M |
| Net Cash Per Share | $0.19 |
| Equity (Book Value) | 6.55M |
| Book Value Per Share | 0.11 |
| Working Capital | 48.57M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -22.80M |
| Capital Expenditures | -480,000 |
| Depreciation & Amortization | 560,000 |
| Net Borrowing | -36,000 |
| Free Cash Flow | -23.28M |
| FCF Per Share | -$0.38 |
Margins
| Measure | Value |
|---|
| Gross Margin | 85.79% |
| Operating Margin | -67.68% |
| Pretax Margin | -62.56% |
| Profit Margin | -62.59% |
| EBITDA Margin | -66.44% |
| EBIT Margin | -67.68% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -73.15% |
| Shareholder Yield | -73.15% |
| Earnings Yield | -31.63% |
| FCF Yield | -10.42% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $10.40 |
| Price Target Difference | 186.50% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 32.36% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.86 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |